论文部分内容阅读
目的对川芎嗪加弥可保治疗糖尿病足的疗效予以观察。方法随机选取该社区卫生服务中心2016年3月—2017年2月收治的10例糖尿病足患者,将其随机均分为治疗组与对照组,在对两组均实行糖尿病常规治疗的基础上,每日对治疗组和对照组分别进行川芎嗪联合弥可保和复方丹参注射液联合维生素B_(12)的治疗,治疗6周后对比分析两组在治疗前后临床疗效和血流速度和足背动脉内径发生的改变。结果通过治疗,两组患者的总有效率及彩色多普勒超声测定患者的血流速度和双侧足背动脉内径差异有统计学意义(P<0.05)。结论和对照组相比之下,治疗组在经过川芎嗪联合弥可保的治疗后,治疗效果较好,且没有特别严重的不良反应。
Objective To observe the curative effect of ligustrazine and mifeprist on diabetic foot. Methods A total of 10 patients with diabetic foot admitted to the community health center from March 2016 to February 2017 were selected randomly and equally divided into treatment group and control group. On the basis of routine treatment of diabetes in both groups, The treatment group and the control group were treated with ligustrazine and mifepristone and compound Danshen injection combined with vitamin B 12 daily. After 6 weeks of treatment, the clinical curative effect, blood flow velocity and dorsal foot were compared between the two groups before and after treatment Arterial diameter changes. Results The total effective rate of the two groups of patients and color Doppler ultrasound measured by the treatment of patients with blood flow velocity and bilateral dorsalis pedis artery diameter difference was statistically significant (P <0.05). Conclusion Compared with the control group, the treatment group after the treatment of ligustrazine combined with miconazole treatment, the treatment effect is good, and no particularly serious adverse reactions.